US FDA Could Be Facing Bolus Of Pandemic-Related Applications
Executive Summary
Acting CDER Director Cavazzoni says it is ‘a very active time’ as many clinical trials for COVID-19-related products are expected to read out soon.
You may also be interested in...
Is Even The Pharma Industry Over COVID-19 Already?
Data suggests fewer approvals and new product ideas, as the business case for new generic and brand treatments seems to be tougher to make now than at other times during the pandemic.
Pandemic Effect: Sponsors Paid Far Fewer User Fees Than Expected In FY 2020
Revenue increases are expected in FY 2021 over pre-pandemic estimates, in part because the US FDA believes sponsors may have applications that were delayed by COVID-19.
Cavazzoni Helms US FDA Drug Center With OTC Monograph Reform Starting, Novel Switches Next
Patrizia Cavazzoni, who likely represents a somewhat different leadership style for CDER, distinguished herself while leading the center temporarily during the COVID-19 pandemic.